tiprankstipranks
Aclaris Therapeutics (GB:0H8T)
LSE:0H8T
UK Market

Aclaris Therapeutics Stock Analysis & Ratings

GB:0H8T Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$12.46
VolumeN/A
Average Volume (3M)792.00
Market Cap$829.61M
P/E RatioN/A
Beta0.38
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)0.00


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:0H8T FAQ

What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Aclaris Therapeutics’s market cap?
    Aclaris Therapeutics’s market cap is $829.61M.
      What is Aclaris Therapeutics’s price target?
      The average price target for Aclaris Therapeutics is $36.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $50.00 ,the lowest forecast is $26.00. The average price target represents 188.92% Increase from the current price of $12.46.
        What do analysts say about Aclaris Therapeutics?
        Aclaris Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Aclaris Therapeutics’s upcoming earnings report date?
          Aclaris Therapeutics’s upcoming earnings report date is Aug 11, 2022 which is in 86 days.
            How were Aclaris Therapeutics’s earnings last quarter?
            Aclaris Therapeutics released its earnings results on May 10, 2022. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.393 by $0.083.
              Is Aclaris Therapeutics overvalued?
              According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
                Does Aclaris Therapeutics pay dividends?
                Aclaris Therapeutics does not currently pay dividends.
                What is Aclaris Therapeutics’s EPS estimate?
                Aclaris Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Aclaris Therapeutics have?
                Aclaris Therapeutics has 66,580,000 shares outstanding.
                  What happened to Aclaris Therapeutics’s price movement after its last earnings report?
                  Aclaris Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.393. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of Aclaris Therapeutics?
                    Among the largest hedge funds holding Aclaris Therapeutics’s share is RA Capital Management. It holds Aclaris Therapeutics’s shares valued at 31M.

                      ---

                      Aclaris Therapeutics Stock Analysis

                      The Aclaris Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Aclaris Therapeutics

                      Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Concert Pharma
                      Novan
                      Rigel
                      Revance Therapeutics

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis